General Information of Drug (ID: DMOGKSW)

Drug Name
PMID25656651-Compound-36c Drug Info
Cross-matching ID
PubChem CID
72203014
TTD Drug ID
DMOGKSW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25656651-Compound-37b DMX98YV N. A. N. A. Patented [1]
PMID25656651-Compound-36a DMNXVY9 N. A. N. A. Patented [1]
PMID25656651-Compound-37c DM684IK N. A. N. A. Patented [1]
PMID25656651-Compound-36d DMKMY4I N. A. N. A. Patented [1]
PMID25656651-Compound-36b DMHYDM7 N. A. N. A. Patented [1]
PMID25656651-Compound-19b DMI1Z7D N. A. N. A. Patented [1]
PMID25656651-Compound-37a DM0P4F3 N. A. N. A. Patented [1]
PMID25656651-Compound-19a DMSNUVZ N. A. N. A. Patented [1]
Indazole derivative 5 DMM1I8R N. A. N. A. Patented [1]
Pyrrolo[2,3-b]pyridine derivative 4 DMJBTZG N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [2]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [2]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [3]
Asciminib DM7EVUF Chronic myeloid leukaemia 2A20 Approved [4]
Radotinib DMWA74Y leukaemia 2A60-2B33 Phase 3 [5]
ABL 001 DMMF5K4 Chronic myeloid leukaemia 2A20 Phase 3 [6]
ICLUSIG DM1SQSE Acute lymphoblastic leukaemia 2A85 Phase 3 [7]
Bafetinib DM7586F Bone disease FC0Z Phase 2 [8]
AN-019 DMJ7QP8 Chronic myelogenous leukaemia 2A20.0 Phase 2 [9]
HQP1351 DMQ30X2 Chronic myeloid leukaemia 2A20 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [1]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [1]

References

1 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
2 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
3 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
4 Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
5 Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
6 ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
7 Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
10 Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.